<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hemiplegic migraine</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hemiplegic migraine</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hemiplegic migraine</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Elizabeth Robertson, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerry W Swanson, MD, MHPE</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 07, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1732684"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hemiplegic migraine is a form of migraine that is characterized by an aura consisting of unilateral weakness along with other symptoms such as impairment of vision, speech, or sensation. Hemiplegic migraine may occur either in families or only in one individual (sporadic).</p><p>This topic will review the pathophysiology, clinical features, diagnosis, and management of familial and sporadic hemiplegic migraine. Other aspects of migraine are discussed elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3348.html" rel="external">"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6161.html" rel="external">"Pathophysiology, clinical features, and diagnosis of migraine in children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3347.html" rel="external">"Acute treatment of migraine in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3345.html" rel="external">"Preventive treatment of episodic migraine in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6168.html" rel="external">"Acute treatment of migraine in children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/98355.html" rel="external">"Preventive treatment of migraine in children"</a>.)</p><p></p><p class="headingAnchor" id="H81875659"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>The primary feature that separates hemiplegic migraine from other types of migraine with aura is the presence of motor weakness as a manifestation of aura in at least some attacks. Migraine auras most often manifest as visual disturbances but can also involve sensory, verbal, and rarely motor disturbances. Thus, hemiplegic migraine is an uncommon subtype of migraine with aura. (See  <a class="medical medical_review" href="/z/d/html/3348.html" rel="external">"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults", section on 'Migraine aura'</a>.)</p><p>Hemiplegic migraine may be familial or sporadic, as discussed in the following section.</p><p class="headingAnchor" id="H1735110"><span class="h1">PATHOPHYSIOLOGY AND GENETICS</span><span class="headingEndMark"> — </span>The weakness that characterizes hemiplegic migraine is a manifestation of motor aura. The aura of hemiplegic migraine is most probably caused by cortical spreading depression, a self-propagating wave of neuronal and glial depolarization that spreads across the cerebral cortex. (See  <a class="medical medical_review" href="/z/d/html/3348.html" rel="external">"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults", section on 'Cortical spreading depression'</a>.)</p><p class="headingAnchor" id="H81876416"><span class="h2">Familial hemiplegic migraine</span><span class="headingEndMark"> — </span>The first three types of familial hemiplegic migraine (FHM) account for some, but not all, of the patients who have familial hemiplegic migraine. They are channelopathies numbered according to the gene involved:</p><p class="bulletIndent1"><span class="glyph">●</span>Familial hemiplegic migraine type 1 (FHM1) is caused by variants in the <em>CACNA1A</em> gene.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Familial hemiplegic migraine type 2 (FHM2) is caused by variants in the <em>ATP1A2</em> gene.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Familial hemiplegic migraine type 3 (FHM3) is caused by variants in the <em>SCN1A</em> gene.</p><p></p><p>Because these types of familial hemiplegic migraine are transmitted in an autosomal dominant pattern, the child of a parent with familial hemiplegic migraine has a 50 percent chance of inheriting the variant, though the penetrance is variable.</p><p>Each genetic variant increases the susceptibility to cortical spreading depression, which most researchers agree initiates the aura of migraine and may initiate the migraine itself in these individuals. (See  <a class="medical medical_review" href="/z/d/html/3348.html" rel="external">"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults", section on 'Cortical spreading depression'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>FHM1</strong> – FHM1 is associated with variants in the <em>CACNA1A</em> gene on chromosome 19p13 that encodes the alpha-1A subunit of the P/Q-type calcium channel [<a href="#rid1">1-5</a>]. The estimated penetrance of <em>CACNA1A</em> variants ranges from 67 to 89 percent [<a href="#rid3">3,6,7</a>].</p><p></p><p class="bulletIndent1">In addition to FHM1, variants in the <em>CACNA1A</em> gene have been implicated in spinocerebellar ataxia type 6, episodic ataxia type 2, and benign paroxysmal torticollis of infancy [<a href="#rid1">1,8,9</a>]. (See  <a class="medical medical_review" href="/z/d/html/6230.html" rel="external">"Autosomal dominant spinocerebellar ataxias", section on 'SCA6'</a> and  <a class="medical medical_review" href="/z/d/html/6234.html" rel="external">"Overview of the hereditary ataxias", section on 'Episodic ataxias'</a> and  <a class="medical medical_review" href="/z/d/html/6462.html" rel="external">"Acquired torticollis in children", section on 'Benign paroxysmal torticollis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>FHM2</strong> – FHM2 is associated with variants in the <em>ATP1A2</em> gene on chromosome 1q23 that encodes a catalytic subunit of a sodium/potassium ATPase [<a href="#rid5">5,10,11</a>]. The estimated penetrance of variants in <em>ATP1A2</em> ranges from 63 to 87 percent [<a href="#rid6">6,7,12</a>].</p><p></p><p class="bulletIndent1">In addition to FHM2, variants in <em>ATP1A2</em> have been associated with migraine with brainstem aura, several types of epilepsy, and rarely with alternating hemiplegia of childhood [<a href="#rid13">13-17</a>]. (See  <a class="medical medical_review" href="/z/d/html/3352.html" rel="external">"Migraine with brainstem aura"</a> and  <a class="medical medical_review" href="/z/d/html/6162.html" rel="external">"Epilepsy syndromes in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>FHM3</strong> – A variant in the <em>SCN1A</em> gene on chromosome 2q24 that encodes the transmembrane alpha subunit of the brain sodium channel has been described in several familial hemiplegic migraine pedigrees [<a href="#rid18">18-22</a>]. The estimated penetrance of variants in <em>SCN1A</em> is 100 percent [<a href="#rid6">6,11,18-21</a>].</p><p></p><p class="bulletIndent1">In addition to FHM3, variants in the <em>SCN1A</em> gene have been linked to a number of epilepsy syndromes. (See  <a class="medical medical_review" href="/z/d/html/6183.html" rel="external">"Clinical features and evaluation of febrile seizures", section on 'Genetic susceptibility'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional types</strong> – The specified types of familial hemiplegic migraine likely account for only a small proportion of cases. The best available evidence comes from a 2007 Danish population-based study that included 44 families with FHM [<a href="#rid7">7</a>]. Variants in the <em>CACNA1A</em> or <em>ATP1A2</em> genes were found in only 14 percent of families, and no <em>SCN1A</em> variants were detected. In addition to these established familial hemiplegic migraine genes, variants in other genes have been reported in familial forms of hemiplegic migraine.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>FHM associated with variants in the </strong><strong><em>PRRT2</em></strong><strong> gene </strong>– Variants in the <em>PRRT2</em> gene, initially recognized as a cause of several paroxysmal disorders, including episodic (or paroxysmal) kinesigenic dyskinesia 1, benign familial infantile epilepsy, and familial infantile convulsions with paroxysmal choreoathetosis, were identified in 2012 as a possible cause of familial hemiplegic migraine [<a href="#rid23">23-26</a>]. In a 2022 analysis of 697 patients with hemiplegic migraine, pathologic variants were found in 105 patients, including 17 percent who were found to have variations in <em>PRRT2</em> [<a href="#rid27">27</a>]. None of these patients had pathologic variants in the <em>CACNA1A</em>, <em>ATP1A2</em>, or <em>SCN1A</em> genes. The estimated penetrance of variants in <em>PRRT2</em> in this cohort was 88 percent. These data suggest variants in <em>PRRT2</em> may represent a fourth type of FHM.</p><p></p><p class="bulletIndent2">While not an ion channel gene,<em> PRRT2</em> encodes a protein that interacts with the synaptosomal-associated protein SNAP25 [<a href="#rid28">28</a>], which may play a role in regulating voltage-gated calcium channels [<a href="#rid29">29,30</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Others genetic variants </strong>– Some cases of familial hemiplegic migraine may be caused by variants in genes other than <em>CACNA1A</em>, <em>ATP1A2</em>, <em>SCN1A</em>, and <em>PRRT2</em>. In a study that examined 101 patients with hemiplegic migraine and no known variant in <em>CACNA1A</em>, <em>ATP1A2</em>, and <em>SCN1A</em>, variants in the <em>PRRT2</em> gene were found in only 4 percent [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent2">Variants in the <em>SLC4A4</em> gene that encode for the <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> cotransporter, a known cause of proximal renal tubular acidosis (RTA) with ocular abnormalities, have been associated with familial forms of migraine in a few patients [<a href="#rid31">31</a>]. The phenotype appears to be variable and includes familial hemiplegic migraine with proximal RTA and typical migraine with or without aura. (See  <a class="medical medical_review" href="/z/d/html/2328.html" rel="external">"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis", section on 'Proximal (type 2) RTA'</a>.)</p><p></p><p class="headingAnchor" id="H81876444"><span class="h2">Sporadic hemiplegic migraine</span><span class="headingEndMark"> — </span>Patients who are the first member of their family to have hemiplegic migraine are classified as having sporadic hemiplegic migraine. Some cases of sporadic hemiplegic migraine are caused by one of the genetic variants that cause familial hemiplegic migraine, due to either de novo mutations or inheritance from an asymptomatic parent [<a href="#rid32">32,33</a>]. In population- and clinic-based studies, variants in the <em>CACNA1A</em> and the <em>ATP1A2</em> genes have been identified in up to 20 percent of patients with sporadic hemiplegic migraine [<a href="#rid6">6,33-35</a>]. However, in patients with severe sporadic hemiplegic migraine associated with additional neurologic manifestations, the frequency of these variants may be much higher [<a href="#rid32">32</a>].</p><p>One patient with sporadic hemiplegic migraine with seizures and ataxia was found to have a variant form of the <em>SLC1A3</em> gene that encodes the glutamate transporter EAAT1 causing neuronal hyperexcitability [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H1732712"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Hemiplegic migraine is a rare disorder. In a population study from Denmark, the estimated prevalence of hemiplegic migraine is 0.01 percent [<a href="#rid37">37</a>]. The familial and sporadic versions occur with equal prevalence [<a href="#rid38">38</a>]. The average age of onset is 12 to 17 years (range 1 to 51 years) [<a href="#rid3">3,38</a>].</p><p>Like other forms of migraine, females have a higher prevalence of hemiplegic migraine, with female to male ratios ranging from 2.5:1 to 4.3:1 [<a href="#rid38">38-40</a>].</p><p class="headingAnchor" id="H1732719"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Hemiplegic migraine is characterized by migraine attacks that include motor weakness during the aura phase. Attacks may variously include severe headache, scintillating scotoma, visual field defect, numbness, paresthesia, unilateral weakness, aphasia, fever, lethargy, coma, and seizures. The symptoms can last for hours to days, or rarely weeks, but most resolve completely. The clinical symptoms of sporadic hemiplegic migraine are indistinguishable from those of familial hemiplegic migraine [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H4282966902"><span class="h2">Attack frequency and triggers</span><span class="headingEndMark"> — </span>The mean frequency of attacks is three per year. However, the attack frequency is quite variable and ranges from a few per lifetime to 250 per year [<a href="#rid42">42</a>]. In many patients, the frequency of attacks falls after age 50 years, and hemiplegic attacks can evolve into more typical migraine attacks without hemiparesis [<a href="#rid3">3,39</a>]. Though most attacks occur without one, reported triggers of hemiplegic migraine attacks include acute stress, bright light, intense emotions, too little or too much sleep, exertion, and mild head trauma [<a href="#rid39">39,42-45</a>]. Attacks have also been triggered by conventional angiography and by <a class="drug drug_general" data-topicid="9462" href="/z/d/drug information/9462.html" rel="external">regadenoson</a>, an agent commonly used for cardiac stress tests [<a href="#rid3">3,46</a>].</p><p class="headingAnchor" id="H1872573547"><span class="h2">Aura</span><span class="headingEndMark"> — </span>Motor aura is the hallmark of hemiplegic migraine, but it is never the only type of aura present during a hemiplegic migraine attack [<a href="#rid3">3,38,40</a>]. Two or more auras are always experienced. Each one tends to evolve over 20 to 30 minutes and may take hours to gradually improve, typically beginning with a visual aura and followed successively by sensory, motor, aphasic, and brainstem symptoms, usually in that order [<a href="#rid38">38</a>]. The aura symptoms associated with migraine with brainstem aura (basilar-type migraine) (see  <a class="medical medical_review" href="/z/d/html/3352.html" rel="external">"Migraine with brainstem aura"</a>) include vertigo, dysarthria, ataxia, bilateral visual, sensory or motor symptoms, hyperacusis, tinnitus, and diminished consciousness [<a href="#rid38">38,40,47</a>].</p><p>Motor symptoms most often start in the hand and gradually spread up into the arm and then the face [<a href="#rid6">6</a>]. The unilateral features of hemiplegic migraine may switch sides between or during attacks. However, bilateral motor signs occur in up to one-third of patients with familial hemiplegic migraine [<a href="#rid3">3</a>], affecting both sides either in succession or simultaneously. The degree of motor weakness can vary from mild to severe [<a href="#rid6">6</a>].</p><p>In a minority, motor weakness or other aura symptoms can develop acutely (ie, in less than five minutes) and may mimic a stroke [<a href="#rid38">38,40</a>]. The auras of hemiplegic migraine are often prolonged; 41 to 58 percent of patients have auras lasting &gt;60 minutes and 2 to 8 percent have auras lasting ≥24 hours [<a href="#rid3">3,38,40,48</a>]. In unusual cases, reversible hemiplegia can last up to four weeks [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H181715012"><span class="h2">Headache</span><span class="headingEndMark"> — </span>Most patients with hemiplegic migraine have headache with each attack [<a href="#rid38">38,40</a>]. The headache usually occurs during the aura, most often after the development of visual disturbances, but may occur before the aura. The headache can be bilateral or unilateral, and unilateral headache may be contralateral or ipsilateral to the aura symptoms [<a href="#rid12">12,49,50</a>]. The severity of headache ranges from mild to excruciating.</p><p class="headingAnchor" id="H905958180"><span class="h2">Other neurologic findings</span><span class="headingEndMark"> — </span>Examination during an attack may reveal the presence of a Babinski sign or unilateral hyperreflexia [<a href="#rid39">39</a>]. Motor and sensory findings more often involve the upper rather than lower limbs [<a href="#rid38">38,39</a>]. In between attacks, most patients have a normal neurologic examination [<a href="#rid38">38</a>], but a majority of patients with familial hemiplegic migraine type 1 (FHM1) [<a href="#rid3">3,51</a>] and a minority with familial hemiplegic migraine type 2 (FHM2) [<a href="#rid12">12,52,53</a>] have cerebellar findings, including gaze-evoked nystagmus, dysarthria, or gait or limb ataxia.</p><p class="headingAnchor" id="H91544380"><span class="h2">Severe attacks</span><span class="headingEndMark"> — </span>In addition to attacks with visual, sensory, motor, aphasic, and brainstem auras, some patients with hemiplegic migraine have more severe attacks accompanied by encephalopathy or coma [<a href="#rid6">6</a>]. Severe attacks affect a variable proportion of patients in different reports, ranging from 1 percent in a population-based study of patients with familial hemiplegic migraine from Denmark [<a href="#rid38">38</a>] to 33 percent in a study of patients with genetic variants in <em>CACNA1A</em> (ie, FHM1) [<a href="#rid3">3</a>]. The encephalopathy can manifest as confusion, agitation, delusions, somnolence, or deep coma [<a href="#rid12">12,54-56</a>]. Seizures, fever, meningismus, cerebrospinal fluid pleocytosis, cerebral edema, or cerebral infarction can also occur with severe attacks [<a href="#rid6">6</a>]. The aura symptoms of severe attacks, including hemiplegia and impaired consciousness, can be prolonged and last days to months before completely resolving [<a href="#rid3">3,52,57-59</a>]. In rare instances, severe attacks can lead to permanent brain injury, cerebral infarction, cerebral atrophy, global or regional hypometabolism, cognitive decline, or death [<a href="#rid60">60-67</a>].</p><p class="headingAnchor" id="H166227735"><span class="h2">Genotype-phenotype correlations</span><span class="headingEndMark"> — </span>The subtypes of familial hemiplegic migraine cannot be reliably distinguished on the basis of clinical features alone. In addition, sporadic hemiplegic migraine cannot be reliably distinguished from the familial type except for the lack of family history. The phenotype of hemiplegic migraine may change within an individual, and often family members suffer different symptoms though they share identical genetic variants [<a href="#rid49">49</a>]. However, there are differences in the range of phenotypic expression of the three specified familial subtypes:</p><p class="bulletIndent1"><span class="glyph">●</span>FHM1 is caused by variants in the <em>CACNA1A</em> gene (see <a class="local">'Familial hemiplegic migraine'</a> above). Approximately half of the families with FHM1 have cerebellar involvement, including gaze-evoked nystagmus, ataxia, and vermian atrophy [<a href="#rid1">1-5</a>]. In addition, some families have severe attacks with coma, prolonged hemiplegia, or both, with full recovery. Transient cerebral edema and cerebral atrophy are uncommon clinical features. Neuronal impairment in the superior cerebellar vermis has been suggested by metabolic alterations found on magnetic resonance spectroscopy [<a href="#rid68">68</a>]. Co-occurrence of familial hemiplegic migraine with childhood epilepsy and cerebellar ataxia in a single family with a variant form of <em>CACNA1A</em> has also been reported [<a href="#rid69">69</a>]. A severe phenotype is associated with the <em>S218L</em> variant of <em>CACNA1A</em>, in which mild head trauma may lead to attacks with prolonged hemiplegia, coma, cerebral edema, or even death [<a href="#rid59">59,60,70</a>]. The <em>R583Q</em> genetic variant is associated with a heterogeneous phenotype in a single large family, with manifestations including various combinations of migraine with aura, transient focal neurologic deficits without headache, cerebellar ataxia, and coma triggered by minor head trauma [<a href="#rid71">71</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>FHM2 is caused by variants in the <em>ATP1A2</em> gene (see <a class="local">'Familial hemiplegic migraine'</a> above). The clinical features of FHM2 are less well-defined than for FHM1, but different <em>ATP1A2</em> variants have been linked to different phenotypes, including frequent and long-lasting hemiplegia, recurrent coma, or seizures with intellectual disability [<a href="#rid5">5,10,12,16,72,73</a>]. Cerebellar involvement has also been described in some patients with FHM2 [<a href="#rid12">12,52,74</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Familial hemiplegic migraine type 3 (FHM3) is caused by variants in the <em>SCN1A</em> gene (see <a class="local">'Familial hemiplegic migraine'</a> above). Only a few families with this genotype have been reported, and the phenotype includes epilepsy [<a href="#rid18">18-20</a>]. In two unrelated families with FHM3, a novel phenotype called elicited repetitive daily blindness has been described, consisting of repetitive stereotyped spells of blindness, usually bilateral, lasting up to 30 seconds followed by instantaneous recovery [<a href="#rid21">21,75</a>]. The visual loss can occur spontaneously or can be triggered by eye rubbing, sudden changes of light, or sudden standing.</p><p></p><p class="headingAnchor" id="H2162026530"><span class="h2">Associated neurologic conditions</span><span class="headingEndMark"> — </span>Patients with hemiplegic migraine may have other associated headache disorders or neurologic conditions.</p><p class="bulletIndent1"><span class="glyph">●</span>Migraine with aura has been associated with familial and sporadic hemiplegic migraine in Danish population studies; no similar association was found with migraine without aura [<a href="#rid76">76,77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Trigeminal autonomic cephalgias may be found in patients with hemiplegic migraine. One report from a tertiary headache referral center observed the co-occurrence in 10 patients of hemiplegic migraine and short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) or short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA) [<a href="#rid78">78</a>]. Both SUNCT and SUNA are rare types of headache that are classified as trigeminal autonomic cephalgias, a group of primary headache disorders characterized by unilateral trigeminal distribution pain that occurs in association with ipsilateral cranial autonomic features. (See  <a class="medical medical_review" href="/z/d/html/3336.html" rel="external">"Short-lasting unilateral neuralgiform headache attacks: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/3339.html" rel="external">"Pathophysiology of the trigeminal autonomic cephalalgias"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic cerebellar ataxia may occur in some patients with familial hemiplegic migraine [<a href="#rid48">48,79</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Epilepsy has also been reported in patients with hemiplegic migraine. In one Danish study, 7 percent of patients with FHM1 were reported to have epilepsy [<a href="#rid38">38</a>]. Benign familial infantile epileptic syndromes have been reported in patients who subsequently developed hemiplegic migraine, including some families with FHM2 [<a href="#rid15">15,80</a>]. </p><p></p><p class="headingAnchor" id="H1732726"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of hemiplegic migraine remains clinical, and genetic testing is not necessary for all patients.</p><p class="headingAnchor" id="H3723388738"><span class="h2">Diagnostic approach</span><span class="headingEndMark"> — </span>Evaluation of patients with headache and neurologic symptoms where the diagnosis of hemiplegic migraine is considered includes the application of established diagnostic criteria and clinical investigations to exclude entities in the differential diagnosis. A diagnosis of hemiplegic migraine is made if the following are satisfied:</p><p class="bulletIndent1"><span class="glyph">●</span>The patient's symptoms fulfill the diagnostic criteria. The key features are the occurrence of episodic, reversible motor weakness as a manifestation of migraine aura in conjunction with at least one other kind of aura (visual, sensory, aphasic, or brainstem). Since motor aura is a necessary feature for the diagnosis, the clinician must establish as clearly as possible whether the patient actually experienced motor weakness as an aura symptom. Although seemingly straightforward, this determination is often challenging because patients may confuse or misinterpret ataxia or numbness as weakness. (See <a class="local">'Diagnostic criteria'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Testing to exclude other considered causes within the differential diagnosis is necessary for patients in whom the diagnosis of hemiplegic migraine is not established, who have prolonged or atypical symptoms, or if the cause of acute symptoms is uncertain. Specific investigations are individualized by patient and guided by symptom characteristics. (See <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/z/d/html/1137.html" rel="external">"Differential diagnosis of transient ischemic attack and acute stroke"</a>.)</p><p></p><p>A thorough family history is essential to distinguish familial from sporadic hemiplegic migraine. In some cases, the diagnosis will change from sporadic to familial hemiplegic migraine over time if a family member develops hemiplegic migraine [<a href="#rid81">81</a>].</p><p class="headingAnchor" id="H1734585"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>The International Classification of Headache Disorders, 3<sup>rd</sup> edition (ICHD-3) diagnostic criteria for hemiplegic migraine require that all of the following be satisfied [<a href="#rid82">82</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>At least two attacks fulfilling criteria for migraine with aura  (<a class="graphic graphic_table graphicRef128907" href="/z/d/graphic/128907.html" rel="external">table 1</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Aura consisting of <strong>both</strong> of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fully reversible motor weakness</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fully reversible visual, sensory, and/or speech or language symptoms</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Not better accounted for by another ICHD-3 diagnosis</p><p></p><p>The ICHD-3 diagnostic criteria for <strong>familial</strong> hemiplegic migraine additionally require that <strong>at least one</strong> first- or second-degree relative has had attacks fulfilling the criteria for hemiplegic migraine [<a href="#rid82">82</a>]. Criteria for <strong>sporadic</strong> hemiplegic migraine specify that <strong>no</strong> first- or second-degree relative has had attacks fulfilling criteria for hemiplegic migraine.</p><p>While the ICHD-3 criteria require fully reversible aura symptoms, in patients with hemiplegic migraine, motor symptoms may be prolonged (eg, up to 72 hours) and rarely may lead to permanent neurologic deficits. (See <a class="local">'Severe attacks'</a> above.)</p><p class="headingAnchor" id="H3413341530"><span class="h2">Tests to exclude other etiologies</span><span class="headingEndMark"> — </span>We recommend diagnostic testing in patients with acute headache and neurologic symptoms to exclude other causes of weakness such as stroke or seizure if:</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms are prolonged or atypical, or</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The cause of acute symptoms is uncertain, or</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient does not already carry a diagnosis of hemiplegic migraine</p><p></p><p>Specific investigations are individualized by patient and guided by symptom characteristics. (See <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/z/d/html/1137.html" rel="external">"Differential diagnosis of transient ischemic attack and acute stroke"</a>.)</p><p class="headingAnchor" id="H2886820909"><span class="h3">Neuroimaging</span><span class="headingEndMark"> — </span>Brain imaging (eg, brain magnetic resonance imaging [MRI] or computed tomography [CT]) in patients with headache and neurologic signs can help identify alternative causes such as intracranial hemorrhage, ischemic stroke, tumors, or abscesses. CT is more readily available than MRI and may be preferred for detecting subarachnoid hemorrhage or structural abnormalities, but MRI is preferred as it is more sensitive for stroke, lesions in the posterior fossa, inflammatory lesions, and neoplasms [<a href="#rid83">83</a>]. The use of neuroimaging is also supported by a practice parameter from the American Academy of Neurology [<a href="#rid84">84</a>]. </p><p>Neurovascular studies (eg, magnetic resonance [MR] angiography or CT angiography) can identify vascular occlusions such as carotid dissection or cerebral venous sinus thrombosis. Conventional contrast cerebral angiography should be avoided if possible, as it is a known trigger of hemiplegic migraine attacks. (See <a class="local">'Attack frequency and triggers'</a> above.)</p><p>During attacks of hemiplegic migraine, brain imaging is usually normal, whether by CT or MRI. In a minority, however, CT or MRI may reveal abnormal findings associated with hemiplegic migraine such as cortical edema and cortical or meningeal enhancement contralateral to the hemiparesis [<a href="#rid36">36,85-87</a>]. In two small studies, susceptibility-weighted MRI during the symptomatic phase of hemiplegic migraine revealed transient prominence of the cerebral veins in brain regions that corresponded with the neurologic deficits [<a href="#rid88">88,89</a>]. In severe cases of hemiplegic migraine, brain MRI may reveal cortical hemispheric atrophy and cortical laminar necrosis [<a href="#rid61">61,90</a>]. Chronic cerebellar atrophy is frequently observed in patients with familial hemiplegic migraine type 1 (FHM1) [<a href="#rid51">51,58</a>]. </p><p>In addition, several studies have demonstrated abnormalities on advanced perfusion-based or nuclear imaging studies. Hyperperfusion may be found on MR perfusion-weighted imaging or single photon emission computed tomography (SPECT) and vasodilation may be identified on noninvasive or conventional angiography. Other reports have found hypoperfusion without infarction, in some cases accompanied by vasoconstriction. These differences may be related in part to the timing of the imaging studies, as migraine aura is initially associated with transient hypoperfusion followed by hyperperfusion [<a href="#rid57">57,61,91-101</a>]. In one patient with sporadic hemiplegic migraine and a genetic variant in the <em>CACNA1A</em> gene who was followed for 15 years, imaging with fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) showed that glucose metabolism was reduced in the bilateral supratentorial cortices and in the left cerebellum [<a href="#rid65">65</a>]. In another report of a patient with familial hemiplegic migraine type 2 (FHM2; caused by a variant in <em>ATP1A2</em>), imaging with 18F-FDG PET during an attack of hemiplegia showed glucose hypometabolism in the contralateral perisylvian cortex that was only partially reversed 78 days later [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H2360463403"><span class="h3">Ancillary testing</span><span class="headingEndMark"> — </span>Routine use of additional investigations such as electroencephalography (EEG) should be reserved for patients with symptoms (eg, loss of consciousness, history of seizures) specifically suggestive of an alternative diagnosis such as seizure [<a href="#rid83">83,102</a>]. Likewise, laboratory testing may be infrequently useful to evaluate specific conditions such as metabolic encephalopathy (eg, hypoglycemia or uremia). Lumbar puncture for cerebrospinal fluid may be useful in evaluating for specific conditions such as subarachnoid hemorrhage or the syndrome of transient headache and neurologic deficits with cerebrospinal fluid lymphocytosis (HaNDL) [<a href="#rid83">83</a>]. The benefit of lumbar puncture needs to be evaluated against the risk of developing post-dural puncture headache. (See <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/z/d/html/113316.html" rel="external">"Post dural puncture headache"</a>.)</p><p class="headingAnchor" id="H4216519373"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>Genetic testing may be useful to help establish the diagnosis of hemiplegic migraine as the cause of severe symptoms in patients without a family history (ie, sporadic cases); in addition, genetic testing may be helpful for cases of familial hemiplegic migraine when the attack severity or symptoms diverge from those of affected relatives [<a href="#rid6">6,32</a>]. However, the yield of genetic testing is low in patients with adult-onset hemiplegic migraine, particularly when there are no associated permanent neurologic features. (See <a class="local">'Pathophysiology and genetics'</a> above.)</p><p class="headingAnchor" id="H1734634"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of hemiplegic migraine primarily includes cerebrovascular disease (eg, transient ischemic attack [TIA] and ischemic or hemorrhagic stroke), seizure with postictal paralysis, other forms of migraine, and tumor. Other entities that may mimic hemiplegic migraine include the syndrome of stroke-like migraine attacks after radiation therapy, HaNDL, alternating hemiplegia of childhood, central nervous system infections, certain hereditary and metabolic disorders, and Sturge-Weber syndrome.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>TIA and ischemic stroke </strong>– The symptoms of TIA and hemiplegic migraine are fully reversible, and neuroimaging is often unrevealing in both conditions. However, both a TIA and an ischemic stroke typically have a sudden onset of symptoms rather than a gradual progressive spread of one aura symptom after another. Ischemic events are also less likely to have positive symptoms such as visual scintillations or paresthesia and are less likely to have migrainous symptoms such as nausea, vomiting, photophobia, and phonophobia (see  <a class="medical medical_review" href="/z/d/html/1137.html" rel="external">"Differential diagnosis of transient ischemic attack and acute stroke"</a>). An exception might be brain ischemia caused by cervical artery dissection, which can have both a progressive spread of symptoms and some migrainous features [<a href="#rid103">103-105</a>]. (See  <a class="medical medical_review" href="/z/d/html/14082.html" rel="external">"Cerebral and cervical artery dissection: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Brain tumors </strong>– Brain tumors typically cause progressive rather than transient neurologic symptoms and are clearly differentiated from hemiplegic migraine by neuroimaging findings of one or more mass lesions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Seizures </strong>– Epilepsy with hemiparesis attributed to postictal (Todd) paralysis is usually distinguished from hemiplegic migraine by paroxysmal symptoms at seizure onset, such as limb jerking, head turning, and loss of consciousness, and by the presence of postictal confusion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SMART syndrome </strong>– The syndrome of stroke-like migraine attacks after radiation therapy (SMART) may include discrete spells of unilateral headache, hemiparesis, hemisensory, and visual and speech impairments that may or may not resolve. SMART should be differentiated from hemiplegic migraine by the history of previous cerebral irradiation and characteristic imaging findings of thick cortical gyral enhancement [<a href="#rid106">106-108</a>]. Patients with SMART syndrome are unlikely to have a family history of hemiplegic migraine and are more likely to have associated seizures. (See  <a class="medical medical_review" href="/z/d/html/91670.html" rel="external">"Delayed complications of cranial irradiation", section on 'Migraine-like headache (SMART) syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HaNDL syndrome </strong>– The syndrome of transient HaNDL, like hemiplegic migraine, may present with episodic headache, hemiparesis, and aphasia and may have ictal regional blood flow abnormalities or be triggered by angiography. Unlike hemiplegic migraine, HaNDL is not familial and is monophasic with resolution in three months. Spinal fluid lymphocytosis is required for the diagnosis of HaNDL, but it has occasionally been found in patients with familial hemiplegic migraine [<a href="#rid3">3,39,109-111</a>]. (See  <a class="medical medical_review" href="/z/d/html/14114.html" rel="external">"Syndrome of transient headache and neurologic deficits with cerebrospinal fluid lymphocytosis (HaNDL)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternating hemiplegia of childhood </strong>– Alternating hemiplegia of childhood (AHC) is a rare condition caused (in the majority of patients) by variants in the <em>ATP1A3</em> gene [<a href="#rid112">112</a>]. In two reports, familial occurrence of AHC was linked to variants in the <em>ATP1A2</em> gene, allelic with FHM2 [<a href="#rid13">13,113</a>] (see <a class="local">'Familial hemiplegic migraine'</a> above). AHC is characterized by periodic episodes of hemiplegia or quadriplegia beginning in infancy [<a href="#rid112">112</a>]. Associated features include dystonia, paroxysmal eye movements (eg, nystagmus), epilepsy [<a href="#rid114">114</a>], cognitive impairment, and ataxia, which help to distinguish it from hemiplegic migraine. (See  <a class="medical medical_review" href="/z/d/html/6202.html" rel="external">"Types of migraine and related syndromes in children", section on 'Alternating hemiplegia of childhood'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other inherited conditions – </strong>The symptomatology of other systemic disorders can include recurrent migraine-like headaches and neurologic deficits. They are distinguished from hemiplegic migraine on the basis of their clinical features, neuroimaging abnormalities, and genetics. These conditions include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The syndrome of mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) [<a href="#rid115">115</a>]. (See  <a class="medical medical_review" href="/z/d/html/5151.html" rel="external">"Mitochondrial myopathies: Clinical features and diagnosis", section on 'MELAS'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) [<a href="#rid116">116</a>]. (See  <a class="medical medical_review" href="/z/d/html/1091.html" rel="external">"Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hereditary hemorrhagic telangiectasia [<a href="#rid117">117</a>]. (See  <a class="medical medical_review" href="/z/d/html/1345.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sturge-Weber syndrome is a rare congenital vascular disorder characterized by facial capillary malformation (port wine birthmark) and associated capillary-venous malformations affecting the brain and eye. While it is not ordinarily confused with hemiplegic migraine, there are case reports of patients with Sturge-Weber syndrome who develop attacks of headache and stroke-like events with paroxysmal hemiparesis [<a href="#rid118">118-120</a>]. (See  <a class="medical medical_review" href="/z/d/html/6159.html" rel="external">"Sturge-Weber syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infections </strong>– Central nervous system infection (meningitis, encephalitis, abscess) can cause headache and hemiparesis, but clinical signs (eg, rash, fever, nuchal rigidity), cerebrospinal fluid analysis (eg, pleocytosis), and neuroimaging findings (eg, meningeal enhancement or parenchymal lesion) usually point to the correct diagnosis. (See  <a class="medical medical_review" href="/z/d/html/1287.html" rel="external">"Clinical features and diagnosis of acute bacterial meningitis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1284.html" rel="external">"Viral encephalitis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1297.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of brain abscess"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolic disturbances </strong>– Some metabolic disturbances, including ornithine transcarbamylase deficiency [<a href="#rid121">121</a>] and homocystinuria [<a href="#rid122">122</a>], can occasionally present with headache and stroke-like attacks but are rarely confused with hemiplegic migraine.</p><p></p><p class="headingAnchor" id="H1732770"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The management of hemiplegic migraine typically involves pharmacologic treatment with agents typically used to abort or prevent migraine that do not potentiate the risk of cerebral vasoconstriction. Because of associated neurologic impairments, patients with severe attacks may require hospitalization and additional measures. (See <a class="local">'Severe attacks'</a> above.)</p><p class="headingAnchor" id="H977692"><span class="h2">Abortive and preventive medications</span><span class="headingEndMark"> — </span>There are no randomized controlled trials of therapy specifically for hemiplegic migraine. However, there is limited evidence from case reports and small series of multiple medications treating hemiplegic migraine.</p><p class="headingAnchor" id="H1972548195"><span class="h3">First-line options</span><span class="headingEndMark"> — </span>Our approach to initial therapy for patients with hemiplegic migraine is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with frequent or prolonged aura, we use oral sustained-release <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a>.</p><p></p><p class="bulletIndent1">Studies involving a small number of patients support the use of <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a> in hemiplegic migraine [<a href="#rid44">44,50,63</a>]. Sustained-release verapamil is started at 120 mg once daily and increased to 120 mg twice daily (total 240 mg daily). The dose can be further titrated up to 120 mg three times a day (total 360 mg daily) for most patients if needed. However, we avoid exceeding a maximum verapamil dose of 120 mg daily for small or older adult patients. In one report of four patients with sporadic hemiplegic migraine, treatment with verapamil (120 mg one to three times a day) was associated with complete resolution of attacks within the first month in two patients and a &gt;50 percent reduction in attack frequency and severity in a third patient [<a href="#rid50">50</a>]. By contrast, other investigators have reported little or no improvement in hemiplegic migraine despite treatment with verapamil [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients in whom the headache pain predominates, we use <a class="drug drug_general" data-topicid="8869" href="/z/d/drug information/8869.html" rel="external">flunarizine</a> (where available), <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>, or <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a>.</p><p></p><p class="bulletIndent1">Hemiplegic migraine may respond to <a class="drug drug_general" data-topicid="8869" href="/z/d/drug information/8869.html" rel="external">flunarizine</a> [<a href="#rid11">11,123,124</a>]. The usual starting dose of flunarizine is 2.5 to 5 mg given once daily (in the evening), and the dose can be further titrated up to 10 mg per day as needed. In one study that included 13 children with hemiplegic migraine, flunarizine (2.5 to 10 mg daily) treatment was associated with a ≥50 percent reduction in attack frequency in 11 (85 percent) [<a href="#rid124">124</a>]. However, flunarizine is unavailable in the United States.</p><p></p><p class="bulletIndent1">Since hemiplegic migraine is a subset of migraine with aura, preventive medications commonly used to treat typical migraine with aura such as <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> or <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> may be beneficial [<a href="#rid125">125,126</a>]. Topiramate is started at 25 mg per day, and the daily dose is increased, as tolerated, by 25 to 50 mg every week to a maximum of 100 mg twice daily. Amitriptyline is started at 10 mg at bedtime and may be increased weekly up to 50 mg at bedtime. (See  <a class="medical medical_review" href="/z/d/html/3345.html" rel="external">"Preventive treatment of episodic migraine in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with familial hemiplegic migraine, we use <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">acetazolamide</a>.</p><p></p><p class="bulletIndent1">Treatment with <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">acetazolamide</a> (250 mg twice a day) is associated with improvement in some patients with familial hemiplegic migraine [<a href="#rid4">4,127,128</a>]. The utility of acetazolamide for hemiplegic migraine is further supported by nonrandomized studies showing its effectiveness in channelopathies that are genetically colocalized with familial hemiplegic migraine type 1 (FHM1) (see <a class="local">'Familial hemiplegic migraine'</a> above). These include hypokalemic periodic paralysis (see  <a class="medical medical_review" href="/z/d/html/5150.html" rel="external">"Hypokalemic periodic paralysis", section on 'Preventive treatment'</a>) and episodic ataxia type 2 (see  <a class="medical medical_review" href="/z/d/html/6234.html" rel="external">"Overview of the hereditary ataxias", section on 'Episodic ataxias'</a>).</p><p></p><p>The decision to continue the medications as preventive therapy after an attack is based upon frequency and severity of attacks, patient preferences regarding use of a daily medication for intermittent symptoms, and whether the agent selected may also effectively treat a separate medical condition. If used as an abortive agent only, these medications are typically discontinued upon resolution of symptoms.</p><p class="headingAnchor" id="H743312572"><span class="h3">Alternative options</span><span class="headingEndMark"> — </span>For adult patients who have persistent aura symptoms that predominate over headache and who do not improve with first-line medications, we suggest <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a>. Other alternative agents that have been examined include intranasal <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a>, intravenous <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a>, and <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a>.</p><p><a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">Lamotrigine</a> is started at 25 mg daily with slow titration in 25 mg steps weekly or biweekly up to 100 mg per day if needed. Lamotrigine was found to be beneficial in a case series of 47 patients who had migraine with aura, including the two patients who had hemiplegic migraine [<a href="#rid129">129</a>]. In a prospective open-label study of 59 patients who had migraine with aura, including eight with motor aura, lamotrigine (25 to 300 mg daily) was associated with a reduction in migraine aura intensity and migraine attack frequency compared with baseline [<a href="#rid130">130</a>]. However, an earlier randomized controlled trial with 77 patients who had migraine with and without typical aura did not demonstrate any benefit of lamotrigine for migraine prophylaxis [<a href="#rid131">131</a>].</p><p>Of concern, a rash may develop in up to 10 percent of patients during the initial one to two months of <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a> therapy, which necessitates discontinuation of the drug. Although the risk of developing Stevens-Johnson syndrome is low (approximately 1 in 1000 adults), it is difficult to initially distinguish between a benign or life-threatening rash. The risk of Stevens-Johnson syndrome is increased dramatically in children, leading to the recommendation that the drug not be used in patients under the age of 16 years. (See  <a class="drug drug_general" href="/z/d/drug information/9545.html" rel="external">"Lamotrigine: Drug information"</a>.)</p><p>Intranasal <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> given at attack onset was associated with a reproducible decrease in the intensity and duration of aura in 5 of 11 patients with familial hemiplegic migraine [<a href="#rid132">132</a>]. In one patient with possible sporadic hemiplegic migraine and another with what was termed "complicated migraine" without hemiplegia, intravenous <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> (0.4 mg) was associated with resolution of the aura-like symptoms, but not the headache pain, within two minutes [<a href="#rid133">133</a>]. (See  <a class="medical medical_review" href="/z/d/html/3345.html" rel="external">"Preventive treatment of episodic migraine in adults"</a> and  <a class="medical medical_review" href="/z/d/html/98355.html" rel="external">"Preventive treatment of migraine in children"</a>.)</p><p>In another case series of 11 patients (4 with familial hemiplegic migraine and 7 with sporadic hemiplegic migraine), a regimen of <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> injections every 12 weeks produced a reduction in frequency and severity of pain and aura associated with hemiplegic migraine episodes [<a href="#rid134">134</a>].</p><p>The use of triptans for hemiplegic migraine is controversial. (See <a class="local">'Medications generally avoided'</a> below.)</p><p class="headingAnchor" id="H3572377102"><span class="h2">Acute management of severe attacks</span><span class="headingEndMark"> — </span>Patients with severe attacks of hemiplegic migraine (see <a class="local">'Severe attacks'</a> above) may require hospital care due to fever, depressed consciousness, or seizures. In addition to usual supportive management of symptoms, therapeutic options for these migraine attacks are the same as for hemiplegic migraine attacks with less severe symptoms [<a href="#rid6">6</a>]. However, patients with recalcitrant severe symptoms may also benefit from treatment with parenteral medications such as corticosteroids.</p><p>Evidence to support the use of corticosteroids is based on individual case reports in the pediatric population. In one case, administration of <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> at 100 mg daily for five days was effective for a child with hemiplegic migraine and severe symptoms [<a href="#rid135">135</a>]. In another, the early treatment of severe attacks with pulse corticosteroids plus hypertonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> seemed beneficial [<a href="#rid136">136</a>]. This report described a child with sporadic hemiplegic migraine and <em>CACNA1A</em>-related encephalopathy who had recurrent attacks of headache, seizures, hemiplegia, coma, and brain edema on MRI. Treatment with intravenous <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (0.5 mg/kg daily divided into three doses per day for three days, followed by gradual oral tapering) and hypertonic saline (3% saline solution given at 1.5 mL/kg per hour, adjusted to maintain sodium levels between 145 and 155 mEq/L, given for two days) was associated with a reduction in seizures and attack duration. It is unclear whether such treatment would be effective for other patients with severe attacks of hemiplegic migraine.</p><p class="headingAnchor" id="H625410"><span class="h2">Medications generally avoided</span><span class="headingEndMark"> — </span>We generally avoid triptans and <a class="drug drug_general" data-topicid="9416" href="/z/d/drug information/9416.html" rel="external">ergotamine</a> derivatives, particularly for patients with severe attacks, because of theoretical concerns and anecdotal evidence that these medications may prolong symptoms or lead to ischemia. In a retrospective case-control study in the Netherlands that included 188 patients hospitalized with ischemic events and 689 age and sex-matched controls, ergotamine overuse was a risk factor for ischemic complications (odds ratio 2.55, 95% CI 1.22-5.36) [<a href="#rid137">137</a>]. Cases of cardiac arrest, cerebral infarcts, and spinal cord infarcts have also been reported in the setting of triptan use [<a href="#rid138">138-142</a>]. In addition, some patients presenting with symptoms consistent with hemiplegic migraine may subsequently be found to have an acute ischemic stroke. Vasoconstrictive medications such as triptans and ergotamines may worsen cerebral ischemia and are felt to be contraindicated in patients with acute stroke. (See  <a class="medical medical_review" href="/z/d/html/3344.html" rel="external">"Migraine-associated stroke: risk factors, diagnosis, and prevention", section on 'Medications to avoid'</a>.)</p><p>However, the theoretical concern about worsening cerebral vasoconstriction in patients with hemiplegic migraine is based primarily upon the relatively outdated vascular theory of migraine, and some have argued that the contraindication for triptans should be reconsidered [<a href="#rid6">6,143</a>]. Patients with hemiplegic migraine were excluded from the larger randomized controlled trials that evaluated triptans for migraine because of historical concerns regarding vasoconstriction. Limited available evidence suggests that triptans do not increase the risk of ischemic events when used for individuals with hemiplegic migraine. In a retrospective series of 76 patients with hemiplegic migraine, for example, triptans appeared to be beneficial and safe for the treatment of the headache phase [<a href="#rid144">144</a>]. There were no ischemic strokes or permanent neurologic complications reported, although one patient had a prolonged attack of hemiplegic migraine that persisted for several months following triptan treatment. In another retrospective series of 13 patients with migraine with brainstem aura (basilar-type migraine), hemiplegic migraine, and prolonged aura exposed to triptans, there was no increased risk of adverse events [<a href="#rid143">143</a>]. (See  <a class="medical medical_review" href="/z/d/html/3348.html" rel="external">"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults", section on 'Pathophysiology'</a>.)</p><p>Some headache specialists also avoid beta blockers and intravenous dihydropyridine calcium channel blockers as preventive therapy for patients who have hemiplegic migraine, migraine with brainstem aura (basilar-type migraine), or migraine with prolonged aura [<a href="#rid145">145</a>]. The concern is that beta blockers may potentially prolong symptoms, limit compensatory cerebral vasodilatory capacitance, or lead to cerebral ischemia [<a href="#rid146">146,147</a>]. Intravenous dihydropyridine calcium channel blockers may potentially lead to cerebral hypoperfusion. In one reported case, intravenous <a class="drug drug_general" data-topicid="9702" href="/z/d/drug information/9702.html" rel="external">nimodipine</a> possibly provoked a seizure during a prolonged attack of hemiplegic migraine in a patient with familial hemiplegic migraine type 2 (FHM2) [<a href="#rid148">148</a>]. (See <a class="local">'Differential diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/1126.html" rel="external">"Initial assessment and management of acute stroke", section on 'Blood pressure management'</a>.)</p><p class="headingAnchor" id="H181715735"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>In nearly all patients with hemiplegic migraine, the aura symptoms eventually resolve completely, though they may be prolonged. However, in rare cases, hemiplegic migraine leads to permanent neurologic deficits, cerebral infarction, cognitive decline, or death [<a href="#rid60">60-64,90,149</a>]. Most such patients have phenotypes characterized by early onset of hemiplegic migraine with severe attacks, recurrent coma, or seizures [<a href="#rid6">6</a>]. (See <a class="local">'Severe attacks'</a> above.)</p><p>In many patients, the frequency of attacks falls after age 50 years, and hemiplegic attacks can evolve into more typical migraine attacks without hemiparesis [<a href="#rid3">3,39</a>].</p><p class="headingAnchor" id="H995607636"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110285.html" rel="external">"Society guideline links: Migraine and other primary headache disorders"</a>.)</p><p class="headingAnchor" id="H9630101"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification and pathophysiology </strong>– Hemiplegic migraine may be familial or sporadic. The three established types of familial hemiplegic migraine (FHM1, FHM2, and FHM3) are autosomal dominant channelopathies that increase the susceptibility to cortical spreading depression and onset of the migraine. Patients who are the first member of their family to have hemiplegic migraine are classified as having sporadic hemiplegic migraine. (See <a class="local">'Pathophysiology and genetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>– Hemiplegic migraine is characterized by complex migraine auras that include motor weakness and at least one other feature such as paresthesia, aphasia, or brainstem impairment. Unilateral or bilateral headache commonly accompanies the aura. Severe cases may also include fever, lethargy, coma, and seizures. The symptoms can last for hours to days, or rarely weeks, but most resolve completely. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical diagnosis </strong>– The diagnosis of hemiplegic migraine is made when symptoms fulfill the diagnostic criteria, including at least two episodes of migraine with reversible complex aura consisting of motor weakness and one or more additional features (visual, sensory, aphasic, or brainstem) and are not better accounted for by another diagnosis. (See <a class="local">'Diagnostic criteria'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic testing </strong>– Diagnostic testing is indicated for patients without an established diagnosis of hemiplegic migraine and for those with prolonged or atypical symptoms. (See <a class="local">'Tests to exclude other etiologies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Brain imaging with CT or MRI can help identify alternative causes such as intracranial hemorrhage, ischemic stroke, tumors, or abscesses. (See <a class="local">'Neuroimaging'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Genetic testing may help to establish the diagnosis in patients who do not have a family history of hemiplegic migraine and in patients whose symptoms are divergent from those of affected relatives with familial hemiplegic migraine. (See <a class="local">'Genetic testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis </strong>– The differential diagnosis of hemiplegic migraine primarily includes cerebrovascular disease (eg, transient ischemic attack and ischemic or hemorrhagic stroke), seizure with postictal paralysis, other forms of migraine, tumor, infections, and certain hereditary and metabolic disorders. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>First line agents </strong>– Our initial therapy for hemiplegic migraine depends upon the clinical presentation and family history. (See <a class="local">'First-line options'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with frequent or prolonged aura, we suggest oral sustained-release <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients for whom the headache pain predominates, we suggest <a class="drug drug_general" data-topicid="8869" href="/z/d/drug information/8869.html" rel="external">flunarizine</a> (where available), <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>, or <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with familial hemiplegic migraine, we suggest <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">acetazolamide</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Alternative choices </strong>– We use <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a> or botulinum toxin as alternative options for patients whose symptoms do not improve with first-line therapies. (See <a class="local">'Alternative options'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medications generally avoided </strong>– We generally avoid triptans and <a class="drug drug_general" data-topicid="9416" href="/z/d/drug information/9416.html" rel="external">ergotamine</a> derivatives to treat patients with symptoms of hemiplegic migraine because of theoretical concerns and anecdotal evidence that these medications may prolong symptoms or lead to ischemia. (See <a class="local">'Medications generally avoided'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis </strong>– In nearly all patients with hemiplegic migraine, the aura symptoms eventually resolve completely, though they may be prolonged. In rare cases, hemiplegic migraine leads to permanent neurologic deficits. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H204236513"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David F Black, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996; 87:543.</a></li><li><a class="nounderline abstract_t">Terwindt GM, Ophoff RA, Haan J, et al. Variable clinical expression of mutations in the P/Q-type calcium channel gene in familial hemiplegic migraine. Dutch Migraine Genetics Research Group. Neurology 1998; 50:1105.</a></li><li><a class="nounderline abstract_t">Ducros A, Denier C, Joutel A, et al. The clinical spectrum of familial hemiplegic migraine associated with mutations in a neuronal calcium channel. N Engl J Med 2001; 345:17.</a></li><li><a class="nounderline abstract_t">Kors EE, Haan J, Giffin NJ, et al. Expanding the phenotypic spectrum of the CACNA1A gene T666M mutation: a description of 5 families with familial hemiplegic migraine. Arch Neurol 2003; 60:684.</a></li><li><a class="nounderline abstract_t">Jen JC, Kim GW, Dudding KA, Baloh RW. No mutations in CACNA1A and ATP1A2 in probands with common types of migraine. Arch Neurol 2004; 61:926.</a></li><li><a class="nounderline abstract_t">Russell MB, Ducros A. Sporadic and familial hemiplegic migraine: pathophysiological mechanisms, clinical characteristics, diagnosis, and management. Lancet Neurol 2011; 10:457.</a></li><li><a class="nounderline abstract_t">Thomsen LL, Kirchmann M, Bjornsson A, et al. The genetic spectrum of a population-based sample of familial hemiplegic migraine. Brain 2007; 130:346.</a></li><li><a class="nounderline abstract_t">Giffin NJ, Benton S, Goadsby PJ. Benign paroxysmal torticollis of infancy: four new cases and linkage to CACNA1A mutation. Dev Med Child Neurol 2002; 44:490.</a></li><li><a class="nounderline abstract_t">Alonso I, Barros J, Tuna A, et al. Phenotypes of spinocerebellar ataxia type 6 and familial hemiplegic migraine caused by a unique CACNA1A missense mutation in patients from a large family. Arch Neurol 2003; 60:610.</a></li><li><a class="nounderline abstract_t">De Fusco M, Marconi R, Silvestri L, et al. Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nat Genet 2003; 33:192.</a></li><li><a class="nounderline abstract_t">De Cunto A, Bensa M, Tonelli A. A case of familial hemiplegic migraine associated with a novel ATP1A2 gene mutation. Pediatr Neurol 2012; 47:133.</a></li><li><a class="nounderline abstract_t">Jurkat-Rott K, Freilinger T, Dreier JP, et al. Variability of familial hemiplegic migraine with novel A1A2 Na+/K+-ATPase variants. Neurology 2004; 62:1857.</a></li><li><a class="nounderline abstract_t">Bassi MT, Bresolin N, Tonelli A, et al. A novel mutation in the ATP1A2 gene causes alternating hemiplegia of childhood. J Med Genet 2004; 41:621.</a></li><li><a class="nounderline abstract_t">Ambrosini A, D'Onofrio M, Grieco GS, et al. Familial basilar migraine associated with a new mutation in the ATP1A2 gene. Neurology 2005; 65:1826.</a></li><li><a class="nounderline abstract_t">Vanmolkot KR, Kors EE, Hottenga JJ, et al. Novel mutations in the Na+, K+-ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions. Ann Neurol 2003; 54:360.</a></li><li><a class="nounderline abstract_t">Al-Bulushi B, Al-Hashem A, Tabarki B. A wide clinical phenotype spectrum in patients with ATP1A2 mutations. J Child Neurol 2014; 29:265.</a></li><li><a class="nounderline abstract_t">Costa C, Prontera P, Sarchielli P, et al. A novel ATP1A2 gene mutation in familial hemiplegic migraine and epilepsy. Cephalalgia 2014; 34:68.</a></li><li><a class="nounderline abstract_t">Dichgans M, Freilinger T, Eckstein G, et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet 2005; 366:371.</a></li><li><a class="nounderline abstract_t">Vanmolkot KR, Babini E, de Vries B, et al. The novel p.L1649Q mutation in the SCN1A epilepsy gene is associated with familial hemiplegic migraine: genetic and functional studies. Mutation in brief #957. Online. Hum Mutat 2007; 28:522.</a></li><li><a class="nounderline abstract_t">Castro MJ, Stam AH, Lemos C, et al. First mutation in the voltage-gated Nav1.1 subunit gene SCN1A with co-occurring familial hemiplegic migraine and epilepsy. Cephalalgia 2009; 29:308.</a></li><li><a class="nounderline abstract_t">Vahedi K, Depienne C, Le Fort D, et al. Elicited repetitive daily blindness: a new phenotype associated with hemiplegic migraine and SCN1A mutations. Neurology 2009; 72:1178.</a></li><li><a class="nounderline abstract_t">Weller CM, Pelzer N, de Vries B, et al. Two novel SCN1A mutations identified in families with familial hemiplegic migraine. Cephalalgia 2014; 34:1062.</a></li><li><a class="nounderline abstract_t">Dale RC, Gardiner A, Antony J, Houlden H. Familial PRRT2 mutation with heterogeneous paroxysmal disorders including paroxysmal torticollis and hemiplegic migraine. Dev Med Child Neurol 2012; 54:958.</a></li><li><a class="nounderline abstract_t">Riant F, Roze E, Barbance C, et al. PRRT2 mutations cause hemiplegic migraine. Neurology 2012; 79:2122.</a></li><li><a class="nounderline abstract_t">Marini C, Conti V, Mei D, et al. PRRT2 mutations in familial infantile seizures, paroxysmal dyskinesia, and hemiplegic migraine. Neurology 2012; 79:2109.</a></li><li><a class="nounderline abstract_t">Ebrahimi-Fakhari D, Saffari A, Westenberger A, Klein C. The evolving spectrum of PRRT2-associated paroxysmal diseases. Brain 2015; 138:3476.</a></li><li><a class="nounderline abstract_t">Riant F, Roos C, Roubertie A, et al. Hemiplegic Migraine Associated With PRRT2 Variations: A Clinical and Genetic Study. Neurology 2022; 98:e51.</a></li><li><a class="nounderline abstract_t">Lee HY, Huang Y, Bruneau N, et al. Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep 2012; 1:2.</a></li><li><a class="nounderline abstract_t">Stelzl U, Worm U, Lalowski M, et al. A human protein-protein interaction network: a resource for annotating the proteome. Cell 2005; 122:957.</a></li><li><a class="nounderline abstract_t">Jarvis SE, Zamponi GW. Masters or slaves? Vesicle release machinery and the regulation of presynaptic calcium channels. Cell Calcium 2005; 37:483.</a></li><li><a class="nounderline abstract_t">Suzuki M, Van Paesschen W, Stalmans I, et al. Defective membrane expression of the Na(+)-HCO(3)(-) cotransporter NBCe1 is associated with familial migraine. Proc Natl Acad Sci U S A 2010; 107:15963.</a></li><li><a class="nounderline abstract_t">Riant F, Ducros A, Ploton C, et al. De novo mutations in ATP1A2 and CACNA1A are frequent in early-onset sporadic hemiplegic migraine. Neurology 2010; 75:967.</a></li><li><a class="nounderline abstract_t">de Vries B, Freilinger T, Vanmolkot KR, et al. Systematic analysis of three FHM genes in 39 sporadic patients with hemiplegic migraine. Neurology 2007; 69:2170.</a></li><li><a class="nounderline abstract_t">Thomsen LL, Oestergaard E, Bjornsson A, et al. Screen for CACNA1A and ATP1A2 mutations in sporadic hemiplegic migraine patients. Cephalalgia 2008; 28:914.</a></li><li><a class="nounderline abstract_t">Hiekkala ME, Vuola P, Artto V, et al. The contribution of CACNA1A, ATP1A2 and SCN1A mutations in hemiplegic migraine: A clinical and genetic study in Finnish migraine families. Cephalalgia 2018; 38:1849.</a></li><li><a class="nounderline abstract_t">Jen JC, Wan J, Palos TP, et al. Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures. Neurology 2005; 65:529.</a></li><li><a class="nounderline abstract_t">Lykke Thomsen L, Kirchmann Eriksen M, Faerch Romer S, et al. An epidemiological survey of hemiplegic migraine. Cephalalgia 2002; 22:361.</a></li><li><a class="nounderline abstract_t">Thomsen LL, Eriksen MK, Roemer SF, et al. A population-based study of familial hemiplegic migraine suggests revised diagnostic criteria. Brain 2002; 125:1379.</a></li><li><a class="nounderline abstract_t">BRADSHAW P, PARSONS M. HEMIPLEGIC MIGRAINE, A CLINICAL STUDY. Q J Med 1965; 34:65.</a></li><li><a class="nounderline abstract_t">Thomsen LL, Ostergaard E, Olesen J, Russell MB. Evidence for a separate type of migraine with aura: sporadic hemiplegic migraine. Neurology 2003; 60:595.</a></li><li><a class="nounderline abstract_t">Thomsen LL, Olesen J. Sporadic hemiplegic migraine. Cephalalgia 2004; 24:1016.</a></li><li><a class="nounderline abstract_t">Terwindt G, Kors E, Haan J, et al. Mutation analysis of the CACNA1A calcium channel subunit gene in 27 patients with sporadic hemiplegic migraine. Arch Neurol 2002; 59:1016.</a></li><li><a class="nounderline abstract_t">WHITTY CW. Familial hemiplegic migraine. J Neurol Neurosurg Psychiatry 1953; 16:172.</a></li><li><a class="nounderline abstract_t">Razavi M, Razavi B, Fattal D, et al. Hemiplegic migraine induced by exertion. Arch Neurol 2000; 57:1363.</a></li><li><a class="nounderline abstract_t">Hansen JM, Hauge AW, Ashina M, Olesen J. Trigger factors for familial hemiplegic migraine. Cephalalgia 2011; 31:1274.</a></li><li><a class="nounderline abstract_t">Elsadany M, McMahon SR, Mehla S, Duvall WL. Hemiplegic migraine episode triggered by regadenoson. J Nucl Cardiol 2022; 29:3469.</a></li><li><a class="nounderline abstract_t">Haan J, Terwindt GM, Ophoff RA, et al. Is familial hemiplegic migraine a hereditary form of basilar migraine? Cephalalgia 1995; 15:477.</a></li><li><a class="nounderline abstract_t">Terwindt GM, Ophoff RA, Haan J, et al. Familial hemiplegic migraine: a clinical comparison of families linked and unlinked to chromosome 19.DMG RG. Cephalalgia 1996; 16:153.</a></li><li><a class="nounderline abstract_t">Ahmed MA, Reid E, Cooke A, et al. Familial hemiplegic migraine in the west of Scotland: a clinical and genetic study of seven families. J Neurol Neurosurg Psychiatry 1996; 61:616.</a></li><li><a class="nounderline abstract_t">Yu W, Horowitz SH. Treatment of sporadic hemiplegic migraine with calcium-channel blocker verapamil. Neurology 2003; 60:120.</a></li><li><a class="nounderline abstract_t">Elliott MA, Peroutka SJ, Welch S, May EF. Familial hemiplegic migraine, nystagmus, and cerebellar atrophy. Ann Neurol 1996; 39:100.</a></li><li><a class="nounderline abstract_t">Spadaro M, Ursu S, Lehmann-Horn F, et al. A G301R Na+/K+ -ATPase mutation causes familial hemiplegic migraine type 2 with cerebellar signs. Neurogenetics 2004; 5:177.</a></li><li><a class="nounderline abstract_t">Fernandez DM, Hand CK, Sweeney BJ, Parfrey NA. A novel ATP1A2 gene mutation in an Irish familial hemiplegic migraine kindred. Headache 2008; 48:101.</a></li><li><a class="nounderline abstract_t">Fitzsimons RB, Wolfenden WH. Migraine coma. Meningitic migraine with cerebral oedema associated with a new form of autosomal dominant cerebellar ataxia. Brain 1985; 108 ( Pt 3):555.</a></li><li><a class="nounderline abstract_t">Münte TF, Müller-Vahl H. Familial migraine coma: a case study. J Neurol 1990; 237:59.</a></li><li><a class="nounderline abstract_t">Spacey SD, Vanmolkot KR, Murphy C, et al. Familial hemiplegic migraine presenting as recurrent encephalopathy in a Native Indian family. Headache 2005; 45:1244.</a></li><li><a class="nounderline abstract_t">Oberndorfer S, Wöber C, Nasel C, et al. Familial hemiplegic migraine: follow-up findings of diffusion-weighted magnetic resonance imaging (MRI), perfusion-MRI and [99mTc] HMPAO-SPECT in a patient with prolonged hemiplegic aura. Cephalalgia 2004; 24:533.</a></li><li><a class="nounderline abstract_t">Vahedi K, Denier C, Ducros A, et al. CACNA1A gene de novo mutation causing hemiplegic migraine, coma, and cerebellar atrophy. Neurology 2000; 55:1040.</a></li><li><a class="nounderline abstract_t">Debiais S, Hommet C, Bonnaud I, et al. The FHM1 mutation S218L: a severe clinical phenotype? A case report and review of the literature. Cephalalgia 2009; 29:1337.</a></li><li><a class="nounderline abstract_t">Kors EE, Terwindt GM, Vermeulen FL, et al. Delayed cerebral edema and fatal coma after minor head trauma: role of the CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine. Ann Neurol 2001; 49:753.</a></li><li><a class="nounderline abstract_t">Hayashi R, Tachikawa H, Watanabe R, et al. Familial hemiplegic migraine with irreversible brain damage. Intern Med 1998; 37:166.</a></li><li><a class="nounderline abstract_t">Vanmolkot KR, Stroink H, Koenderink JB, et al. Severe episodic neurological deficits and permanent mental retardation in a child with a novel FHM2 ATP1A2 mutation. Ann Neurol 2006; 59:310.</a></li><li><a class="nounderline abstract_t">Knierim E, Leisle L, Wagner C, et al. Recurrent stroke due to a novel voltage sensor mutation in Cav2.1 responds to verapamil. Stroke 2011; 42:e14.</a></li><li><a class="nounderline abstract_t">Dodick D, Roarke M. Familial hemiplegic migraine: permanent attack-related neurologic deficits. Headache 2007; 47:1210.</a></li><li><a class="nounderline abstract_t">Topakian R, Pischinger B, Stieglbauer K, Pichler R. Rare clinical findings in a patient with sporadic hemiplegic migraine: FDG-PET provides diminished brain metabolism at 10-year follow-up. Cephalalgia 2014; 34:392.</a></li><li><a class="nounderline abstract_t">Guedj E, Belenotti P, Serratrice J, et al. Partially reversible cortical metabolic dysfunction in familial hemiplegic migraine with prolonged aura. Headache 2010; 50:872.</a></li><li><a class="nounderline abstract_t">Pelzer N, Hoogeveen ES, Ferrari MD, et al. Brain atrophy following hemiplegic migraine attacks. Cephalalgia 2018; 38:1199.</a></li><li><a class="nounderline abstract_t">Dichgans M, Herzog J, Freilinger T, et al. 1H-MRS alterations in the cerebellum of patients with familial hemiplegic migraine type 1. Neurology 2005; 64:608.</a></li><li><a class="nounderline abstract_t">Kors EE, Melberg A, Vanmolkot KR, et al. Childhood epilepsy, familial hemiplegic migraine, cerebellar ataxia, and a new CACNA1A mutation. Neurology 2004; 63:1136.</a></li><li><a class="nounderline abstract_t">Stam AH, Luijckx GJ, Poll-Thé BT, et al. Early seizures and cerebral oedema after trivial head trauma associated with the CACNA1A S218L mutation. J Neurol Neurosurg Psychiatry 2009; 80:1125.</a></li><li><a class="nounderline abstract_t">Barros J, Damásio J, Tuna A, et al. Cerebellar ataxia, hemiplegic migraine, and related phenotypes due to a CACNA1A missense mutation: 12-year follow-up of a large Portuguese family. JAMA Neurol 2013; 70:235.</a></li><li><a class="nounderline abstract_t">Roth C, Freilinger T, Kirovski G, et al. Clinical spectrum in three families with familial hemiplegic migraine type 2 including a novel mutation in the ATP1A2 gene. Cephalalgia 2014; 34:183.</a></li><li><a class="nounderline abstract_t">Pelzer N, Blom DE, Stam AH, et al. Recurrent coma and fever in familial hemiplegic migraine type 2. A prospective 15-year follow-up of a large family with a novel ATP1A2 mutation. Cephalalgia 2016.</a></li><li><a class="nounderline abstract_t">Grimaldi D, Tonon C, Cevoli S, et al. Clinical and neuroimaging evidence of interictal cerebellar dysfunction in FHM2. Cephalalgia 2010; 30:552.</a></li><li><a class="nounderline abstract_t">Le Fort D, Safran AB, Picard F, et al. Elicited repetitive daily blindness: a new familial disorder related to migraine and epilepsy. Neurology 2004; 63:348.</a></li><li><a class="nounderline abstract_t">Thomsen LL, Olesen J, Russell MB. Increased risk of migraine with typical aura in probands with familial hemiplegic migraine and their relatives. Eur J Neurol 2003; 10:421.</a></li><li><a class="nounderline abstract_t">Thomsen LL, Ostergaard E, Romer SF, et al. Sporadic hemiplegic migraine is an aetiologically heterogeneous disorder. Cephalalgia 2003; 23:921.</a></li><li><a class="nounderline abstract_t">Lambru G, Nesbitt A, Shanahan P, Matharu MS. Coexistence of hemiplegic migraine with SUNCT or SUNA: a case series. Cephalalgia 2012; 32:258.</a></li><li><a class="nounderline abstract_t">Cricchi F, Di Lorenzo C, Grieco GS, et al. Early-onset progressive ataxia associated with the first CACNA1A mutation identified within the I-II loop. J Neurol Sci 2007; 254:69.</a></li><li><a class="nounderline abstract_t">Terwindt GM, Ophoff RA, Lindhout D, et al. Partial cosegregation of familial hemiplegic migraine and a benign familial infantile epileptic syndrome. Epilepsia 1997; 38:915.</a></li><li><a class="nounderline abstract_t">Stam AH, Louter MA, Haan J, et al. A long-term follow-up study of 18 patients with sporadic hemiplegic migraine. Cephalalgia 2011; 31:199.</a></li><li><a class="nounderline abstract_t">Olesen J. International Classification of Headache Disorders. Lancet Neurol 2018; 17:396.</a></li><li><a class="nounderline abstract_t">Evans RW. Diagnostic Testing for Migraine and Other Primary Headaches. Neurol Clin 2019; 37:707.</a></li><li><a class="nounderline abstract_t">Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:754.</a></li><li><a class="nounderline abstract_t">Cha YH, Millett D, Kane M, et al. Adult-onset hemiplegic migraine with cortical enhancement and oedema. Cephalalgia 2007; 27:1166.</a></li><li><a class="nounderline abstract_t">Dreier JP, Jurkat-Rott K, Petzold GC, et al. Opening of the blood-brain barrier preceding cortical edema in a severe attack of FHM type II. Neurology 2005; 64:2145.</a></li><li><a class="nounderline abstract_t">Pellerin A, Marois C, Mezouar N, et al. Neuronal injuries evidenced by transient cortical magnetic resonance enhancement in hemiplegic migraine: A case report. Cephalalgia 2019; 39:323.</a></li><li><a class="nounderline abstract_t">Fedak EM, Zumberge NA, Heyer GL. The diagnostic role for susceptibility-weighted MRI during sporadic hemiplegic migraine. Cephalalgia 2013; 33:1258.</a></li><li><a class="nounderline abstract_t">Bosemani T, Burton VJ, Felling RJ, et al. Pediatric hemiplegic migraine: role of multiple MRI techniques in evaluation of reversible hypoperfusion. Cephalalgia 2014; 34:311.</a></li><li><a class="nounderline abstract_t">Black DF, Kung S, Sola CL, et al. Familial hemiplegic migraine, neuropsychiatric symptoms, and Erdheim-Chester disease. Headache 2004; 44:911.</a></li><li><a class="nounderline abstract_t">Lindahl AJ, Allder S, Jefferson D, et al. Prolonged hemiplegic migraine associated with unilateral hyperperfusion on perfusion weighted magnetic resonance imaging. J Neurol Neurosurg Psychiatry 2002; 73:202.</a></li><li><a class="nounderline abstract_t">Barbour PJ, Castaldo JE, Shoemaker EI. Hemiplegic migraine during pregnancy: unusual magnetic resonance appearance with SPECT scan correlation. Headache 2001; 41:310.</a></li><li><a class="nounderline abstract_t">Masuzaki M, Utsunomiya H, Yasumoto S, Mitsudome A. A case of hemiplegic migraine in childhood: transient unilateral hyperperfusion revealed by perfusion MR imaging and MR angiography. AJNR Am J Neuroradiol 2001; 22:1795.</a></li><li><a class="nounderline abstract_t">Hsu DA, Stafstrom CE, Rowley HA, et al. Hemiplegic migraine: hyperperfusion and abortive therapy with intravenous verapamil. Brain Dev 2008; 30:86.</a></li><li><a class="nounderline abstract_t">Iizuka T, Takahashi Y, Sato M, et al. Neurovascular changes in prolonged migraine aura in FHM with a novel ATP1A2 gene mutation. J Neurol Neurosurg Psychiatry 2012; 83:205.</a></li><li><a class="nounderline abstract_t">Gonzalez-Alegre P, Tippin J. Prolonged cortical electrical depression and diffuse vasospasm without ischemia in a case of severe hemiplegic migraine during pregnancy. Headache 2003; 43:72.</a></li><li><a class="nounderline abstract_t">Pierelli F, Pauri F, Cupini LM, et al. Transcranial Doppler sonography in familial hemiplegic migraine. Cephalalgia 1991; 11:29.</a></li><li><a class="nounderline abstract_t">Prodan CI, Holland NR, Lenaerts ME, Parke JT. Magnetic resonance angiogram evidence of vasospasm in familial hemiplegic migraine. J Child Neurol 2002; 17:470.</a></li><li><a class="nounderline abstract_t">Hansen JM, Schytz HW, Larsen VA, et al. Hemiplegic migraine aura begins with cerebral hypoperfusion: imaging in the acute phase. Headache 2011; 51:1289.</a></li><li><a class="nounderline abstract_t">Safier R, Cleves-Bayon C, Vaisleib I, et al. Magnetic resonance angiography evidence of vasospasm in children with suspected acute hemiplegic migraine. J Child Neurol 2014; 29:789.</a></li><li><a class="nounderline abstract_t">Mourand I, Menjot de Champfleur N, Carra-Dallière C, et al. Perfusion-weighted MR imaging in persistent hemiplegic migraine. Neuroradiology 2012; 54:255.</a></li><li><a class="nounderline abstract_t">Gronseth GS, Greenberg MK. The utility of the electroencephalogram in the evaluation of patients presenting with headache: a review of the literature. Neurology 1995; 45:1263.</a></li><li><a class="nounderline abstract_t">Silverman IE, Wityk RJ. Transient migraine-like symptoms with internal carotid artery dissection. Clin Neurol Neurosurg 1998; 100:116.</a></li><li><a class="nounderline abstract_t">Mirza Z, Hayward P, Hulbert D. Spontaneous carotid artery dissection presenting as migraine--a diagnosis not to be missed. J Accid Emerg Med 1998; 15:187.</a></li><li><a class="nounderline abstract_t">Haraguchi K, Toyama K, Ito T, et al. A case of posterior cerebral artery dissection presenting with migraine-like headache and visual field defect: usefulness of fast imaging employing steady-state acquisition (FIESTA) for diagnosis. J Stroke Cerebrovasc Dis 2012; 21:906.e5.</a></li><li><a class="nounderline abstract_t">Bartleson JD, Krecke KN, O'Neill BP, Brown PD. Reversible, strokelike migraine attacks in patients with previous radiation therapy. Neuro Oncol 2003; 5:121.</a></li><li><a class="nounderline abstract_t">Black DF, Bartleson JD, Bell ML, Lachance DH. SMART: stroke-like migraine attacks after radiation therapy. Cephalalgia 2006; 26:1137.</a></li><li><a class="nounderline abstract_t">Kerklaan JP, Lycklama á Nijeholt GJ, Wiggenraad RG, et al. SMART syndrome: a late reversible complication after radiation therapy for brain tumours. J Neurol 2011; 258:1098.</a></li><li><a class="nounderline abstract_t">Berg MJ, Williams LS. The transient syndrome of headache with neurologic deficits and CSF lymphocytosis. Neurology 1995; 45:1648.</a></li><li><a class="nounderline abstract_t">Fuentes B, Diez Tejedor E, Pascual J, et al. Cerebral blood flow changes in pseudomigraine with pleocytosis analyzed by single photon emission computed tomography. A spreading depression mechanism? Cephalalgia 1998; 18:570.</a></li><li><a class="nounderline abstract_t">De Benedittis G, Ferrari Da Passano C, Granata G, Lorenzetti A. CBF changes during headache-free periods and spontaneous/induced attacks in migraine with and without aura: a TCD and SPECT comparison study. J Neurosurg Sci 1999; 43:141.</a></li><li><a class="nounderline abstract_t">Kansagra S, Mikati MA, Vigevano F. Alternating hemiplegia of childhood. Handb Clin Neurol 2013; 112:821.</a></li><li><a class="nounderline abstract_t">Swoboda KJ, Kanavakis E, Xaidara A, et al. Alternating hemiplegia of childhood or familial hemiplegic migraine? A novel ATP1A2 mutation. Ann Neurol 2004; 55:884.</a></li><li><a class="nounderline abstract_t">Uchitel J, Helseth A, Prange L, et al. The epileptology of alternating hemiplegia of childhood. Neurology 2019; 93:e1248.</a></li><li><a class="nounderline abstract_t">Koo B, Becker LE, Chuang S, et al. Mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes (MELAS): clinical, radiological, pathological, and genetic observations. Ann Neurol 1993; 34:25.</a></li><li><a class="nounderline abstract_t">Monteiro C, Barros J, Taipa R, Pereira-Monteiro J. Sporadic hemiplegic migraine with normal imaging as the initial manifestation of CADASIL. Cephalalgia 2012; 32:255.</a></li><li><a class="nounderline abstract_t">Steele JG, Nath PU, Burn J, Porteous ME. An association between migrainous aura and hereditary haemorrhagic telangiectasia. Headache 1993; 33:145.</a></li><li><a class="nounderline abstract_t">Dora B, Balkan S. Sporadic hemiplegic migraine and Sturge-Weber syndrome. Headache 2001; 41:209.</a></li><li><a class="nounderline abstract_t">Jung A, Raman A, Rowland Hill C. Acute hemiparesis in Sturge-Weber syndrome. Pract Neurol 2009; 9:169.</a></li><li><a class="nounderline abstract_t">Planche V, Chassin O, Leduc L, et al. Sturge-Weber syndrome with late onset hemiplegic migraine-like attacks and progressive unilateral cerebral atrophy. Cephalalgia 2014; 34:73.</a></li><li><a class="nounderline abstract_t">de Grauw TJ, Smit LM, Brockstedt M, et al. Acute hemiparesis as the presenting sign in a heterozygote for ornithine transcarbamylase deficiency. Neuropediatrics 1990; 21:133.</a></li><li><a class="nounderline abstract_t">Silva GS, Almeida CM, Félix EP, et al. [Cerebral venous thrombosis and homocystinuria: case report]. Arq Neuropsiquiatr 2001; 59:815.</a></li><li><a class="nounderline abstract_t">Tobita M, Hino M, Ichikawa N, et al. A case of hemiplegic migraine treated with flunarizine. Headache 1987; 27:487.</a></li><li><a class="nounderline abstract_t">Peer Mohamed B, Goadsby PJ, Prabhakar P. Safety and efficacy of flunarizine in childhood migraine: 11 years' experience, with emphasis on its effect in hemiplegic migraine. Dev Med Child Neurol 2012; 54:274.</a></li><li><a class="nounderline abstract_t">Pelzer N, Stam AH, Haan J, et al. Familial and sporadic hemiplegic migraine: diagnosis and treatment. Curr Treat Options Neurol 2013; 15:13.</a></li><li><a class="nounderline abstract_t">Zarcone D, Corbetta S. Shared mechanisms of epilepsy, migraine and affective disorders. Neurol Sci 2017; 38:73.</a></li><li><a class="nounderline abstract_t">Athwal BS, Lennox GG. Acetazolamide responsiveness in familial hemiplegic migraine. Ann Neurol 1996; 40:820.</a></li><li><a class="nounderline abstract_t">Battistini S, Stenirri S, Piatti M, et al. A new CACNA1A gene mutation in acetazolamide-responsive familial hemiplegic migraine and ataxia. Neurology 1999; 53:38.</a></li><li><a class="nounderline abstract_t">Pascual J, Caminero AB, Mateos V, et al. Preventing disturbing migraine aura with lamotrigine: an open study. Headache 2004; 44:1024.</a></li><li><a class="nounderline abstract_t">Lampl C, Katsarava Z, Diener HC, Limmroth V. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry 2005; 76:1730.</a></li><li><a class="nounderline abstract_t">Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997; 17:109.</a></li><li><a class="nounderline abstract_t">Kaube H, Herzog J, Käufer T, et al. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology 2000; 55:139.</a></li><li><a class="nounderline abstract_t">Centonze V, Brucoli C, Macinagrossa G, et al. Non-familial hemiplegic migraine responsive to naloxone. Cephalalgia 1983; 3:125.</a></li><li><a class="nounderline abstract_t">Chen TY, Garza I, Dodick DW, Robertson CE. The Effect of OnabotulinumtoxinA on Aura Frequency and Severity in Patients With Hemiplegic Migraine: Case Series of 11 Patients. Headache 2018; 58:973.</a></li><li><a class="nounderline abstract_t">Sánchez-Albisua I, Schöning M, Jurkat-Rott K, Lerche H. Possible effect of corticoids on hemiplegic attacks in severe hemiplegic migraine. Pediatr Neurol 2013; 49:286.</a></li><li><a class="nounderline abstract_t">Camia F, Pisciotta L, Morana G, et al. Combined early treatment in hemiplegic attacks related to CACNA1A encephalopathy with brain oedema: Blocking the cascade? Cephalalgia 2017; 37:1202.</a></li><li><a class="nounderline abstract_t">Wammes-van der Heijden EA, Rahimtoola H, Leufkens HG, et al. Risk of ischemic complications related to the intensity of triptan and ergotamine use. Neurology 2006; 67:1128.</a></li><li><a class="nounderline abstract_t">Main ML, Ramaswamy K, Andrews TC. Cardiac arrest and myocardial infarction immediately after sumatriptan injection. Ann Intern Med 1998; 128:874.</a></li><li><a class="nounderline abstract_t">Jayamaha JE, Street MK. Fatal cerebellar infarction in a migraine sufferer whilst receiving sumatriptan. Intensive Care Med 1995; 21:82.</a></li><li><a class="nounderline abstract_t">Kato Y, Hayashi T, Mizuno S, et al. Triptan-induced Reversible Cerebral Vasoconstriction Syndrome: Two Case Reports with a Literature Review. Intern Med 2016; 55:3525.</a></li><li><a class="nounderline abstract_t">Vijayan N, Peacock JH. Spinal cord infarction during use of zolmitriptan: a case report. Headache 2000; 40:57.</a></li><li><a class="nounderline abstract_t">Aboul Nour H, Miller DJ, Danoun OA. Naratriptan-Associated Spinal Artery Infarction. Am J Ther 2021; 28:e734.</a></li><li><a class="nounderline abstract_t">Klapper J, Mathew N, Nett R. Triptans in the treatment of basilar migraine and migraine with prolonged aura. Headache 2001; 41:981.</a></li><li><a class="nounderline abstract_t">Artto V, Nissilä M, Wessman M, et al. Treatment of hemiplegic migraine with triptans. Eur J Neurol 2007; 14:1053.</a></li><li><a class="nounderline abstract_t">Evans RW, Lipton RB. Topics in migraine management: a survey of headache specialists highlights some controversies. Neurol Clin 2001; 19:1.</a></li><li><a class="nounderline abstract_t">Prendes JL. Considerations on the use of propranolol in complicated migraine. Headache 1980; 20:93.</a></li><li><a class="nounderline abstract_t">Gilbert GJ. An occurrence of complicated migraine during propranolol therapy. Headache 1982; 22:81.</a></li><li><a class="nounderline abstract_t">Mjåset C, Russell MB. Intravenous nimodipine worsening prolonged attack of familial hemiplegic migraine. J Headache Pain 2008; 9:381.</a></li><li><a class="nounderline abstract_t">Schwedt TJ, Zhou J, Dodick DW. Sporadic hemiplegic migraine with permanent neurological deficits. Headache 2014; 54:163.</a></li></ol></div><div id="topicVersionRevision">Topic 14112 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8898206" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9566402" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Variable clinical expression of mutations in the P/Q-type calcium channel gene in familial hemiplegic migraine. Dutch Migraine Genetics Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11439943" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The clinical spectrum of familial hemiplegic migraine associated with mutations in a neuronal calcium channel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12756131" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Expanding the phenotypic spectrum of the CACNA1A gene T666M mutation: a description of 5 families with familial hemiplegic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15210532" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : No mutations in CACNA1A and ATP1A2 in probands with common types of migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21458376" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Sporadic and familial hemiplegic migraine: pathophysiological mechanisms, clinical characteristics, diagnosis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17142831" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The genetic spectrum of a population-based sample of familial hemiplegic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12162387" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Benign paroxysmal torticollis of infancy: four new cases and linkage to CACNA1A mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12707077" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Phenotypes of spinocerebellar ataxia type 6 and familial hemiplegic migraine caused by a unique CACNA1A missense mutation in patients from a large family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12539047" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22759692" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A case of familial hemiplegic migraine associated with a novel ATP1A2 gene mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15159495" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Variability of familial hemiplegic migraine with novel A1A2 Na+/K+-ATPase variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15286158" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A novel mutation in the ATP1A2 gene causes alternating hemiplegia of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16344534" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Familial basilar migraine associated with a new mutation in the ATP1A2 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12953268" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Novel mutations in the Na+, K+-ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24097848" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A wide clinical phenotype spectrum in patients with ATP1A2 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23918834" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A novel ATP1A2 gene mutation in familial hemiplegic migraine and epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16054936" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17397047" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The novel p.L1649Q mutation in the SCN1A epilepsy gene is associated with familial hemiplegic migraine: genetic and functional studies. Mutation in brief #957. Online.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19220312" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : First mutation in the voltage-gated Nav1.1 subunit gene SCN1A with co-occurring familial hemiplegic migraine and epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19332696" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Elicited repetitive daily blindness: a new phenotype associated with hemiplegic migraine and SCN1A mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24707016" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Two novel SCN1A mutations identified in families with familial hemiplegic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22845787" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Familial PRRT2 mutation with heterogeneous paroxysmal disorders including paroxysmal torticollis and hemiplegic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23077016" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : PRRT2 mutations cause hemiplegic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23077026" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : PRRT2 mutations in familial infantile seizures, paroxysmal dyskinesia, and hemiplegic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26598493" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The evolving spectrum of PRRT2-associated paroxysmal diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34649875" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Hemiplegic Migraine Associated With PRRT2 Variations: A Clinical and Genetic Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22832103" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16169070" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A human protein-protein interaction network: a resource for annotating the proteome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15820397" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Masters or slaves? Vesicle release machinery and the regulation of presynaptic calcium channels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20798035" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Defective membrane expression of the Na(+)-HCO(3)(-) cotransporter NBCe1 is associated with familial migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20837964" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : De novo mutations in ATP1A2 and CACNA1A are frequent in early-onset sporadic hemiplegic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18056581" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Systematic analysis of three FHM genes in 39 sporadic patients with hemiplegic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18513263" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Screen for CACNA1A and ATP1A2 mutations in sporadic hemiplegic migraine patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29486580" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The contribution of CACNA1A, ATP1A2 and SCN1A mutations in hemiplegic migraine: A clinical and genetic study in Finnish migraine families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16116111" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12110112" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : An epidemiological survey of hemiplegic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12023326" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A population-based study of familial hemiplegic migraine suggests revised diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14252427" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : HEMIPLEGIC MIGRAINE, A CLINICAL STUDY.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12601098" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Evidence for a separate type of migraine with aura: sporadic hemiplegic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15566415" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Sporadic hemiplegic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12056940" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Mutation analysis of the CACNA1A calcium channel subunit gene in 27 patients with sporadic hemiplegic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13085199" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Familial hemiplegic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10987906" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Hemiplegic migraine induced by exertion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21784774" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Trigger factors for familial hemiplegic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34308528" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Hemiplegic migraine episode triggered by regadenoson.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8706110" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Is familial hemiplegic migraine a hereditary form of basilar migraine?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8734765" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Familial hemiplegic migraine: a clinical comparison of families linked and unlinked to chromosome 19.DMG RG.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8971111" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Familial hemiplegic migraine in the west of Scotland: a clinical and genetic study of seven families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12525732" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Treatment of sporadic hemiplegic migraine with calcium-channel blocker verapamil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8572654" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Familial hemiplegic migraine, nystagmus, and cerebellar atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15459825" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A G301R Na+/K+ -ATPase mutation causes familial hemiplegic migraine type 2 with cerebellar signs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18184292" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A novel ATP1A2 gene mutation in an Irish familial hemiplegic migraine kindred.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4041774" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Migraine coma. Meningitic migraine with cerebral oedema associated with a new form of autosomal dominant cerebellar ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2319269" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Familial migraine coma: a case study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16178956" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Familial hemiplegic migraine presenting as recurrent encephalopathy in a Native Indian family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15196295" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Familial hemiplegic migraine: follow-up findings of diffusion-weighted magnetic resonance imaging (MRI), perfusion-MRI and [99mTc] HMPAO-SPECT in a patient with prolonged hemiplegic aura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11061267" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : CACNA1A gene de novo mutation causing hemiplegic migraine, coma, and cerebellar atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19438926" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The FHM1 mutation S218L: a severe clinical phenotype? A case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11409427" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Delayed cerebral edema and fatal coma after minor head trauma: role of the CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9550598" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Familial hemiplegic migraine with irreversible brain damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16437583" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Severe episodic neurological deficits and permanent mental retardation in a child with a novel FHM2 ATP1A2 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21183743" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Recurrent stroke due to a novel voltage sensor mutation in Cav2.1 responds to verapamil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17883529" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Familial hemiplegic migraine: permanent attack-related neurologic deficits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24270521" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Rare clinical findings in a patient with sporadic hemiplegic migraine: FDG-PET provides diminished brain metabolism at 10-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20236346" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Partially reversible cortical metabolic dysfunction in familial hemiplegic migraine with prolonged aura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28750589" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Brain atrophy following hemiplegic migraine attacks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728280" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : 1H-MRS alterations in the cerebellum of patients with familial hemiplegic migraine type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15452324" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Childhood epilepsy, familial hemiplegic migraine, cerebellar ataxia, and a new CACNA1A mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19520699" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Early seizures and cerebral oedema after trivial head trauma associated with the CACNA1A S218L mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23407676" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Cerebellar ataxia, hemiplegic migraine, and related phenotypes due to a CACNA1A missense mutation: 12-year follow-up of a large Portuguese family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24096472" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Clinical spectrum in three families with familial hemiplegic migraine type 2 including a novel mutation in the ATP1A2 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27226003" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Recurrent coma and fever in familial hemiplegic migraine type 2. A prospective 15-year follow-up of a large family with a novel ATP1A2 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19673908" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Clinical and neuroimaging evidence of interictal cerebellar dysfunction in FHM2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15277634" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Elicited repetitive daily blindness: a new familial disorder related to migraine and epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12823495" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Increased risk of migraine with typical aura in probands with familial hemiplegic migraine and their relatives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14616935" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Sporadic hemiplegic migraine is an aetiologically heterogeneous disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22238357" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Coexistence of hemiplegic migraine with SUNCT or SUNA: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17292920" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Early-onset progressive ataxia associated with the first CACNA1A mutation identified within the I-II loop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9579893" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Partial cosegregation of familial hemiplegic migraine and a benign familial infantile epileptic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20974584" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A long-term follow-up study of 18 patients with sporadic hemiplegic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29550365" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : International Classification of Headache Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31563228" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Diagnostic Testing for Migraine and Other Primary Headaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10993991" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17645764" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Adult-onset hemiplegic migraine with cortical enhancement and oedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15985592" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Opening of the blood-brain barrier preceding cortical edema in a severe attack of FHM type II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30092648" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Neuronal injuries evidenced by transient cortical magnetic resonance enhancement in hemiplegic migraine: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23766355" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The diagnostic role for susceptibility-weighted MRI during sporadic hemiplegic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24142848" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Pediatric hemiplegic migraine: role of multiple MRI techniques in evaluation of reversible hypoperfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15447701" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Familial hemiplegic migraine, neuropsychiatric symptoms, and Erdheim-Chester disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12122185" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Prolonged hemiplegic migraine associated with unilateral hyperperfusion on perfusion weighted magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11264693" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Hemiplegic migraine during pregnancy: unusual magnetic resonance appearance with SPECT scan correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11673182" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A case of hemiplegic migraine in childhood: transient unilateral hyperperfusion revealed by perfusion MR imaging and MR angiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17614229" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Hemiplegic migraine: hyperperfusion and abortive therapy with intravenous verapamil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22013243" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Neurovascular changes in prolonged migraine aura in FHM with a novel ATP1A2 gene mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12864763" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Prolonged cortical electrical depression and diffuse vasospasm without ischemia in a case of severe hemiplegic migraine during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2036667" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Transcranial Doppler sonography in familial hemiplegic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12174974" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Magnetic resonance angiogram evidence of vasospasm in familial hemiplegic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21797860" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Hemiplegic migraine aura begins with cerebral hypoperfusion: imaging in the acute phase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23594822" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Magnetic resonance angiography evidence of vasospasm in children with suspected acute hemiplegic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21833737" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Perfusion-weighted MR imaging in persistent hemiplegic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7617180" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The utility of the electroencephalogram in the evaluation of patients presenting with headache: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9746299" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Transient migraine-like symptoms with internal carotid artery dissection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9639183" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Spontaneous carotid artery dissection presenting as migraine--a diagnosis not to be missed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22177933" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : A case of posterior cerebral artery dissection presenting with migraine-like headache and visual field defect: usefulness of fast imaging employing steady-state acquisition (FIESTA) for diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12672284" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Reversible, strokelike migraine attacks in patients with previous radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16919065" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : SMART: stroke-like migraine attacks after radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21373901" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : SMART syndrome: a late reversible complication after radiation therapy for brain tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7675221" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : The transient syndrome of headache with neurologic deficits and CSF lymphocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9827250" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Cerebral blood flow changes in pseudomigraine with pleocytosis analyzed by single photon emission computed tomography. A spreading depression mechanism?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10735768" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : CBF changes during headache-free periods and spontaneous/induced attacks in migraine with and without aura: a TCD and SPECT comparison study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23622289" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Alternating hemiplegia of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15174025" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Alternating hemiplegia of childhood or familial hemiplegic migraine? A novel ATP1A2 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31484714" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : The epileptology of alternating hemiplegia of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8517676" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes (MELAS): clinical, radiological, pathological, and genetic observations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22250206" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Sporadic hemiplegic migraine with normal imaging as the initial manifestation of CADASIL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8486513" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : An association between migrainous aura and hereditary haemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11251712" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Sporadic hemiplegic migraine and Sturge-Weber syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19448061" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Acute hemiparesis in Sturge-Weber syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24045571" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Sturge-Weber syndrome with late onset hemiplegic migraine-like attacks and progressive unilateral cerebral atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2234317" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Acute hemiparesis as the presenting sign in a heterozygote for ornithine transcarbamylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11593291" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : [Cerebral venous thrombosis and homocystinuria: case report].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3692829" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : A case of hemiplegic migraine treated with flunarizine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22268377" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Safety and efficacy of flunarizine in childhood migraine: 11 years' experience, with emphasis on its effect in hemiplegic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23203776" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Familial and sporadic hemiplegic migraine: diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28527083" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Shared mechanisms of epilepsy, migraine and affective disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8957029" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Acetazolamide responsiveness in familial hemiplegic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10408534" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : A new CACNA1A gene mutation in acetazolamide-responsive familial hemiplegic migraine and ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15546267" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Preventing disturbing migraine aura with lamotrigine: an open study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16291905" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9137848" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Lamotrigine versus placebo in the prophylaxis of migraine with and without aura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10891926" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6871987" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Non-familial hemiplegic migraine responsive to naloxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29762872" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : The Effect of OnabotulinumtoxinA on Aura Frequency and Severity in Patients With Hemiplegic Migraine: Case Series of 11 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23831250" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Possible effect of corticoids on hemiplegic attacks in severe hemiplegic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27651281" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Combined early treatment in hemiplegic attacks related to CACNA1A encephalopathy with brain oedema: Blocking the cascade?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17030745" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Risk of ischemic complications related to the intensity of triptan and ergotamine use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9599209" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Cardiac arrest and myocardial infarction immediately after sumatriptan injection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7560482" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Fatal cerebellar infarction in a migraine sufferer whilst receiving sumatriptan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27904122" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Triptan-induced Reversible Cerebral Vasoconstriction Syndrome: Two Case Reports with a Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10759907" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Spinal cord infarction during use of zolmitriptan: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33491969" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Naratriptan-Associated Spinal Artery Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11903526" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Triptans in the treatment of basilar migraine and migraine with prolonged aura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17718700" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Treatment of hemiplegic migraine with triptans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11471758" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Topics in migraine management: a survey of headache specialists highlights some controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7372478" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Considerations on the use of propranolol in complicated migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7085266" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : An occurrence of complicated migraine during propranolol therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18846413" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Intravenous nimodipine worsening prolonged attack of familial hemiplegic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24117121" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Sporadic hemiplegic migraine with permanent neurological deficits.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
